Bioepis JV Sale To Provide Needed Cash To Biogen
Plus Independence For Korean Partner
Executive Summary
Biogen may find itself with new business options after agreeing to sell its stake in the Samsung Bioepis biosimilars joint venture for up to $2.3bn.